Lantheus
Lantheus
LNTH
NASDAQ
106.47
USD
13.27%
About
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships.
Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its pipeline also includes breast and other cancers. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology.
Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, Ga-DOTA-RM2, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 828.4K |
| Three Month Average Volume | 22.7M |
| High Low | |
| Fifty-Two Week High | 126.8899 USD |
| Fifty-Two Week Low | 50.2 USD |
| Fifty-Two Week High Date | 16 Jul 2024 |
| Fifty-Two Week Low Date | 23 Jan 2024 |
| Price and Volume | |
| Current Price | 106.47 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 3.27% |
| Thirteen Week Relative Price Change | 21.57% |
| Twenty-Six Week Relative Price Change | 49.80% |
| Fifty-Two Week Relative Price Change | 24.15% |
| Year-to-Date Relative Price Change | 45.02% |
| Price Change | |
| One Day Price Change | 1.58% |
| Thirteen Week Price Change | 30.11% |
| Twenty-Six Week Price Change | 64.71% |
| Five Day Price Change | -0.64% |
| Fifty-Two Week Price Change | 55.57% |
| Year-to-Date Price Change | 71.73% |
| Month-to-Date Price Change | 1.56% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 11.90666 USD |
| Book Value Per Share (Most Recent Quarter) | 14.79139 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 8.79572 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 11.4284 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 7.30367 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 18.4574 USD |
| Revenue Per Share (Trailing Twelve Months) | 20.47763 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 4.65071 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 6.10656 USD |
| Normalized (Last Fiscal Year) | 5.73388 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 4.78512 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 6.23859 USD |
| Including Extraordinary Items (Last Fiscal Year) | 4.65071 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 6.10656 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 10.41469 USD |
| Cash Per Share (Most Recent Quarter) | 10.90631 USD |
| Cash Flow Per Share (Last Fiscal Year) | 5.50555 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 6.95505 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | 4.57825 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 17 |
| Cash Flow Revenue (Trailing Twelve Months) | 22 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 38.53% |
| Pretax Margin (Last Fiscal Year) | 31.70% |
| Pretax Margin (5 Year) | 11.36% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 64.17% |
| Gross Margin (Trailing Twelve Months) | 64.49% |
| Gross Margin (5 Year) | 57.56% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 28.13% |
| Operating Margin (Trailing Twelve Months) | 31.93% |
| Operating Margin (5 Year) | 11.50% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 25.20% |
| Net Profit Margin (Trailing Twelve Months) | 29.80% |
| Net Profit Margin (5 Year) | 9.02% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 45.18% |
| Tangible Book Value (5 Year) | 67.18% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | 39.04% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 22.50% |
| Revenue Growth (3 Year) | 30.44% |
| Revenue Change (Trailing Twelve Months) | 27.83% |
| Revenue Per Share Growth | 16.25% |
| Revenue Growth (5 Year) | 56.32% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 35.48% |
| Total Debt (5 Year) | 16.12% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -33.67% |
| EPS Change (Trailing Twelve Months) | 1,405.08% |
| EPS Growth (3 Year) | 35.30% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | 48.81% |
| EBITDA (5 Year Interim) | 45.91% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | 16.38% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 12 |
| Price to Tangible Book (Most Recent Quarter) | 9 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 35 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 23 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -192,962,000 |
| Net Debt (Last Fiscal Year) | -151,163,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 6 |
| Price to Sales (Trailing Twelve Months) | 5 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 17 |
| PE Normalized (Last Fiscal Year) | 19 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 13 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 207 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 9 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 17 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 9 |
| Price to Book (Most Recent Quarter) | 7 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 69 |
| Long Term Debt to Equity (Most Recent Quarter) | 55 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 0.00% |
| Payout Ratio (Trailing Twelve Months) | 0.00% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 5 |
| Quick Ratio (Most Recent Quarter) | 4 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 25 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 20 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 213.4M |
| Free Cash Flow (Trailing Twelve Months) | 321.5M |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | 1.3K |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 69 |
| Total Debt to Equity (Most Recent Quarter) | 55 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 21.98% |
| Return on Assets (Trailing Twelve Months) | 26.15% |
| Return on Assets (5 Year) | 6.69% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 51.73% |
| Return on Equity (Trailing Twelve Months) | 54.26% |
| Return on Equity (5 Year) | 15.21% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 25.75% |
| Return on Investment (Trailing Twelve Months) | 29.96% |
| Return on Investment (5 Year) | 7.73% |